Clinical trial AV-951-15-303
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma
| Cancers | |
|---|---|
| Organ | Kidney cells carcinoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Aveo Oncology |
| EudraCT Identifier | 2015-003607-30 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02627963 |
| Inclusion criteria | 2 or 3 prior regimens, including one with VEGFR TKI |
| Last update |